DK1297851T3 - Inhibering af histondeacetylasesom behandling af hjertehypertrofi - Google Patents

Inhibering af histondeacetylasesom behandling af hjertehypertrofi

Info

Publication number
DK1297851T3
DK1297851T3 DK02021676T DK02021676T DK1297851T3 DK 1297851 T3 DK1297851 T3 DK 1297851T3 DK 02021676 T DK02021676 T DK 02021676T DK 02021676 T DK02021676 T DK 02021676T DK 1297851 T3 DK1297851 T3 DK 1297851T3
Authority
DK
Denmark
Prior art keywords
cardiac hypertrophy
inhibition
treatment
histone deacetylase
gene expression
Prior art date
Application number
DK02021676T
Other languages
Danish (da)
English (en)
Inventor
Michael R Bristow
Carlin Long
Timothy A Mckinsey
Eric N Olson
Original Assignee
Univ Colorado
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado, Univ Texas filed Critical Univ Colorado
Application granted granted Critical
Publication of DK1297851T3 publication Critical patent/DK1297851T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK02021676T 2001-09-27 2002-09-27 Inhibering af histondeacetylasesom behandling af hjertehypertrofi DK1297851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US33404101P 2001-10-31 2001-10-31

Publications (1)

Publication Number Publication Date
DK1297851T3 true DK1297851T3 (da) 2005-05-30

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02021676T DK1297851T3 (da) 2001-09-27 2002-09-27 Inhibering af histondeacetylasesom behandling af hjertehypertrofi

Country Status (8)

Country Link
US (4) US6706686B2 (ja)
EP (1) EP1297851B1 (ja)
JP (2) JP2003238445A (ja)
AT (1) ATE287731T1 (ja)
DE (1) DE60202727T2 (ja)
DK (1) DK1297851T3 (ja)
ES (1) ES2236415T3 (ja)
PT (1) PT1297851E (ja)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350086A1 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
WO2004082638A2 (en) 2003-03-17 2004-09-30 Syrrx, Inc. Histone deacetylase inhibitors
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
AU2004270150C1 (en) * 2003-08-29 2011-07-14 Merck Hdac Research, Llc Combination methods of treating cancer
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005074941A1 (en) * 2004-02-02 2005-08-18 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
WO2005097088A2 (en) * 2004-04-05 2005-10-20 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
ES2701704T3 (es) 2004-04-07 2019-02-25 Ncardia Ag Sistemas de ensayo tisulares funcionales no invasivos in vitro
DK1745144T3 (da) 2004-05-11 2011-02-07 Axiogenesis Ag Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006088949A1 (en) 2005-02-14 2006-08-24 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
US20070015777A1 (en) * 2005-07-14 2007-01-18 Myogen, Inc. Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
RU2008108909A (ru) * 2005-08-10 2009-09-20 Новартис АГ (CH) Способ применения ингибиторов деацетилазы
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1962888A2 (en) * 2005-11-18 2008-09-03 Myogen, Inc. Uses for camkii and hdacs in the treatment of heart conditions
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2647359A1 (en) * 2006-03-29 2007-11-08 Edward Via Virginia College Of Osteopathic Medicine Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
US20090312311A1 (en) * 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
CA2648384A1 (en) * 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
CA2650520A1 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2124990A4 (en) * 2006-12-29 2010-04-21 Gloucester Pharmaceuticals Inc TUMOR TREATMENT BASED ON ROMIDEPSIN
CA2674309A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
US9884031B2 (en) * 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
WO2009048540A1 (en) * 2007-10-05 2009-04-16 U.S. Department Of Veterans Affairs Office Of General Counsel - Psg Iv (024) Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2010039697A2 (en) * 2008-09-30 2010-04-08 Gilead Sciences, Inc. Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
JP6049614B2 (ja) 2010-07-12 2016-12-21 セルジーン コーポレイション ロミデプシン固体形態及びそれらの使用
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
RS58895B1 (sr) 2010-10-13 2019-08-30 Medivir Ab Farmaceutska formulacija za inhibitore histonske deacetilaze
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP2023508907A (ja) 2019-12-20 2023-03-06 テナヤ セラピューティクス， インコーポレイテッド フルオロアルキル－オキサジアゾールおよびその使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6060311A (en) * 1995-07-28 2000-05-09 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
EP1123111B1 (en) 1998-10-19 2004-09-15 Methylgene, Inc. Modulation of dna methyltransferase expression by combination therapy
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
AU6718200A (en) 1999-05-03 2000-12-12 Methylgene, Inc. Inhibition of histone deacetylase
WO2001014581A2 (en) 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU7108400A (en) * 1999-09-03 2001-04-10 Salk Institute For Biological Studies, The Modulation of gene expression by modulating histone acetylation
AU781380B2 (en) 1999-09-07 2005-05-19 Conjuchem Biotechnologies Inc. Pulmonary delivery for bioconjugation
EP1212357B1 (en) 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
WO2001042437A2 (en) 1999-12-08 2001-06-14 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
AU2001298014A1 (en) 2000-03-24 2003-01-29 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
EP1280764B1 (en) 2000-03-24 2010-11-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US6888027B2 (en) 2000-09-29 2005-05-03 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
WO2002050285A2 (en) 2000-12-20 2002-06-27 Novartis Ag Histone deacetylase-related gene and protein
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
US20060069014A1 (en) 2006-03-30
US20040186049A1 (en) 2004-09-23
EP1297851A1 (en) 2003-04-02
US20060025333A1 (en) 2006-02-02
JP2010001311A (ja) 2010-01-07
DE60202727D1 (de) 2005-03-03
JP2003238445A (ja) 2003-08-27
US6946441B2 (en) 2005-09-20
ATE287731T1 (de) 2005-02-15
ES2236415T3 (es) 2005-07-16
US20030144340A1 (en) 2003-07-31
PT1297851E (pt) 2005-06-30
EP1297851B1 (en) 2005-01-26
US6706686B2 (en) 2004-03-16
DE60202727T2 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
DK1297851T3 (da) Inhibering af histondeacetylasesom behandling af hjertehypertrofi
DK1233958T3 (da) Hæmmere af histondeacetylase
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE463490T1 (de) Histondeacetylase-hemmer
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
EP1777225A4 (en) FUSED BENZAMIDE COMPOUND AND INHIBITOR OF VANILLOID RECEPTOR 1 (VR1) ACTIVITY
EA200802329A1 (ru) Производные триазола ii
DE69924135D1 (de) Heterozyklische kalium-kanal inhibitoren
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
MXPA04002397A (es) Inhibidores de histona deacetilasa.
PT1423391E (pt) Pirrolopirimidinas como agentes para a inibicao de proteases de cisteina
EA200200976A1 (ru) Способ лечения или ингибирования полипов ободочной кишки
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
IN2005KO00312A (ja)
EA200701782A2 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
DK1511472T3 (da) Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor
ATE443044T1 (de) Tace inhibitoren
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
WO2004089901A3 (en) Phospholipase c inhibitors for use in treating inflammatory disorders